Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Vivian E. Drory is active.

Publication


Featured researches published by Vivian E. Drory.


Lancet Neurology | 2012

Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: A cross-sectional study

Elisa Majounie; Alan E. Renton; Kin Mok; Elise G.P. Dopper; Adrian James Waite; Sara Rollinson; Adriano Chiò; Gabriella Restagno; Nayia Nicolaou; Javier Simón-Sánchez; John C. van Swieten; Yevgeniya Abramzon; Janel O. Johnson; Michael Sendtner; Roger Pamphlett; Richard W. Orrell; Simon Mead; Katie Sidle; Henry Houlden; Jonathan D. Rohrer; Karen E. Morrison; Hardev Pall; Kevin Talbot; Olaf Ansorge; Dena Hernandez; Sampath Arepalli; Mario Sabatelli; Gabriele Mora; Massimo Corbo; Fabio Giannini

Summary Background We aimed to accurately estimate the frequency of a hexanucleotide repeat expansion in C9orf72 that has been associated with a large proportion of cases of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Methods We screened 4448 patients diagnosed with ALS (El Escorial criteria) and 1425 patients with FTD (Lund-Manchester criteria) from 17 regions worldwide for the GGGGCC hexanucleotide expansion using a repeat-primed PCR assay. We assessed familial disease status on the basis of self-reported family history of similar neurodegenerative diseases at the time of sample collection. We compared haplotype data for 262 patients carrying the expansion with the known Finnish founder risk haplotype across the chromosomal locus. We calculated age-related penetrance using the Kaplan-Meier method with data for 603 individuals with the expansion. Findings In patients with sporadic ALS, we identified the repeat expansion in 236 (7·0%) of 3377 white individuals from the USA, Europe, and Australia, two (4·1%) of 49 black individuals from the USA, and six (8·3%) of 72 Hispanic individuals from the USA. The mutation was present in 217 (39·3%) of 552 white individuals with familial ALS from Europe and the USA. 59 (6·0%) of 981 white Europeans with sporadic FTD had the mutation, as did 99 (24·8%) of 400 white Europeans with familial FTD. Data for other ethnic groups were sparse, but we identified one Asian patient with familial ALS (from 20 assessed) and two with familial FTD (from three assessed) who carried the mutation. The mutation was not carried by the three Native Americans or 360 patients from Asia or the Pacific Islands with sporadic ALS who were tested, or by 41 Asian patients with sporadic FTD. All patients with the repeat expansion had (partly or fully) the founder haplotype, suggesting a one-off expansion occurring about 1500 years ago. The pathogenic expansion was non-penetrant in individuals younger than 35 years, 50% penetrant by 58 years, and almost fully penetrant by 80 years. Interpretation A common Mendelian genetic lesion in C9orf72 is implicated in many cases of sporadic and familial ALS and FTD. Testing for this pathogenic expansion should be considered in the management and genetic counselling of patients with these fatal neurodegenerative diseases. Funding Full funding sources listed at end of paper (see Acknowledgments).


Nature Neuroscience | 2012

Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis

Chi Hong Wu; Claudia Fallini; Nicola Ticozzi; Pamela Keagle; Peter C. Sapp; Katarzyna Piotrowska; Patrick Lowe; Max Koppers; Diane McKenna-Yasek; Desiree M. Baron; Jason E. Kost; Paloma Gonzalez-Perez; Andrew Fox; Jenni Adams; Franco Taroni; Cinzia Tiloca; Ashley Lyn Leclerc; Shawn C. Chafe; Dev Mangroo; Melissa J. Moore; Jill A. Zitzewitz; Zuo Shang Xu; Leonard H. van den Berg; Jonathan D. Glass; Gabriele Siciliano; Elizabeth T. Cirulli; David B. Goldstein; François Salachas; Vincent Meininger; Wilfried Rossoll

MATR3 is an RNA- and DNA-binding protein that interacts with TDP-43, a disease protein linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Using exome sequencing, we identified mutations in MATR3 in ALS kindreds. We also observed MATR3 pathology in ALS-affected spinal cords with and without MATR3 mutations. Our data provide more evidence supporting the role of aberrant RNA processing in motor neuron degeneration.


Journal of the Neurological Sciences | 2001

The value of muscle exercise in patients with amyotrophic lateral sclerosis

Vivian E. Drory; Evgeny Goltsman; Jacqueline Goldman Reznik; Amnon Mosek; Amos D. Korczyn

The role of physical activity for patients with amyotrophic lateral sclerosis (ALS) is controversial. Twenty-five ALS patients were randomized to receive a moderate daily exercise program (n=14) or not to perform any physical activity beyond their usual daily requirements (n=11). At baseline and after 3, 6, 9 and 12 months, patients were assessed by manual muscle strength testing, the Ashworth spasticity scale, ALS functional rating scale (FRS), fatigue severity scale, a visual analogue scale for musculoskeletal pain and the quality-of-life scale (SF-36). At 3 months, patients who performed regular exercise showed less deterioration on FRS and Ashworth scales, but not on other parameters. At 6 months, there was no significant difference between groups, although a trend towards less deterioration in the treated group on most scales was observed. At 9 and 12 months, there were too few patients in each group for statistical evaluation. Our results show that a regular moderate physical exercise program has a short-lived positive effect on disability in ALS patients and should be recommended.


Journal of the Neurological Sciences | 2001

Association of APOE ε4 allele with survival in amyotrophic lateral sclerosis

Vivian E. Drory; Miriam Birnbaum; Amos D. Korczyn; Joab Chapman

Abstract APOE e4 allele is associated with poorer outcome in degenerative neurological diseases. Its role in amyotrophic lateral sclerosis (ALS) is still unclear. The aim of the present study was to further analyze the association of APOE e4 allele with progression and survival of ALS. One hundred consecutive ALS patients (53 males) and 133 controls were genotyped for the APOE e4 allele. The association of this allele with survival to death or tracheostomy was analyzed by Kaplan–Meier survival analysis. The frequency of the APOE e4 allele in ALS patients was slightly higher (15.1%) than in the control group (10.9%). Patients with or without an APOE e4 allele had a similar age of onset and frequency of bulbar onset. There was a significant shortening of the 50% probability of survival (by 32 months) in patients carrying the APOE e4 allele ( p =0.03). In conclusion, carrying an APOE e4 allele is a poor prognostic factor in ALS. This is compatible with a role of apolipoprotein on neuronal survival and repair.


Amyotrophic Lateral Sclerosis | 2015

A revision of the El Escorial criteria - 2015

Albert C. Ludolph; Vivian E. Drory; Orla Hardiman; Imaharu Nakano; John Ravits; Wim Robberecht; Jeremy M. Shefner

There has been much discussion as to the necessity for adjustment of the El Escorial diagnostic criteria, primarily based on observations relating to the specificity of the‘Possible’ category. The ...


Neurology | 1993

Sympathetic skin response Age effect

Vivian E. Drory; Amos D. Korczyn

We examined the sympathetic skin response in 100 normal subjects aged 20 to 91 years. The response was present in all younger subjects, but, in the elderly, was present in the lower limbs of only 50% and in the upper limbs of 73%. The amplitude of the response showed a marked decline with age in both the upper and lower limbs.


Journal of the Neurological Sciences | 2009

Do patients with amyotrophic lateral sclerosis (ALS) have increased energy needs

Nachum Vaisman; Michal Lusaus; Beatrice Nefussy; Eva Niv; Doron Comaneshter; Ron Hallack; Vivian E. Drory

BACKGROUND AND AIMS Nutritional status is a prognostic factor for survival in amyotrophic lateral sclerosis (ALS) patients. We investigated the contribution of some of the components contributing to resting energy expenditure (REE) in order to determine whether potentially higher energy needs should be considered for these patients. METHODS Thirty three ALS patients and 33 age- and gender-matched healthy controls participated. REE was measured by an open-circuit indirect calorimeter, body composition by dual energy X-ray absorptiometry, and estimated caloric intake by 7-day food records. RESULTS Patients had lower body mass indices and lower lean body mass (LBM) than healthy controls. REE values (as a percentage of predicted) was similar but increased when normalized by LBM (P<0.001). LBM and REE decreased while REE/LBM increased in ten patients who were reassessed 6 months later. A model for predicting measured REE was constructed based on the different components, with 86% prediction of its variability. CONCLUSIONS ALS is associated with increased REE. Various factors, such as poor caloric intake and mechanical ventilation, may mask this tendency. All the above parameters need to be considered during nutritional intervention to prevent additional muscle loss.


Amyotrophic Lateral Sclerosis | 2009

Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial

Vincent Meininger; Vivian E. Drory; P. Nigel Leigh; Albert C. Ludolph; Wim Robberecht; Vincenzo Silani

Our objective was to assess the efficacy and safety of 40 mg/day glatiramer acetate (GA) in patients with ALS. We conducted a double-blind, randomized, placebo-controlled, multicentre trial. Three hundred and sixty-six patients with definite, probable or probable laboratory supported ALS and a slow vital capacity ≥ 70% were randomly assigned to treatment with placebo or 40 mg GA daily. The primary intention-to-treat analysis was the comparison between the two treated groups of the rates of deterioration on the ALSFRSR scale. The secondary outcome measure was time to death, tracheostomy or permanent assisted ventilation. Safety and tolerability of GA were evaluated. After 52 weeks of follow-up, the slope of the ALSFRSR score was comparable in the both groups (placebo, −1.00±0.06/month; GA, −1.05±0.06/month; p=0.48). The secondary endpoint was non-significant with 159 patients (87.4%) alive in the placebo group and 162 patients (88.1%) in the GA group (log rank, p=0.75). The most common events were the injection site reactions (76.1% in the GA group, 14.8% in the placebo group), comparable to the known profile of 20 mg GA. In conclusion, GA at a dose of 40 mg/day did not show any beneficial effect in ALS patients, and safety and tolerability of GA were good in this population.


Amyotrophic Lateral Sclerosis | 2009

Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: A pilot study

Beatrice Nefussy; Irena Artamonov; Varda Deutsch; Ela Naparstek; Arnon Nagler; Vivian E. Drory

Granulocyte-colony stimulating factor (G-CSF) is used to mobilize CD34+ haematopoietic stem cells from the bone marrow to the peripheral blood. We proposed to use cell subsets induced by G-CSF to slow down disease progression in patients with amyotrophic lateral sclerosis (ALS). Patients with definite or probable ALS were assigned in a double-blind manner to receive G-CSF or placebo every three months for a year. The primary outcome measure was the functional decline, measured by the revised ALS Functional Rating Scale, Revised (ALSFRS-R) score. Secondary outcome measures included vital capacity, manual muscle strength, compound muscle action potential amplitudes, neurophysiological index, and McGill single item quality of life score (QoL). Thirty-nine patients were enrolled. Seventeen patients who received G-CSF and 18 who received placebo were evaluated. G-CSF was effective in mobilizing CD34+ to blood. The outcome measures used showed no statistically significant benefit, although there was a trend of slowing disease progression following two G-CSF treatments, as shown by lower slopes of ALSFRS-R and QoL in the first six treatment months. The treatment had no major side-effects. G-CSF administration in ALS patients caused successful mobilization of autologous bone marrow cells, but was not effective in slowing down disease deterioration.


Clinical Neuropharmacology | 1993

Hypersensitivity Vasculitis and Systemic Lupus Erythematosus Induced by Anticonvulsants

Vivian E. Drory; Amos D. Korczyn

Vasculitis can be a systemic manifestation of hypersensitivity to many drugs, among them anticonvulsants. The clinical manifestations include rash and renal, hepatic, and pulmonary involvement. Diagnosis is based upon clinical findings and a characteristic biopsy showing granulocytic and sometimes eosinophilic infiltrates around small blood vessels, especially venules. A severe form of hypersensitivity vasculitis, with extensive visceral involvement and poor prognosis, has been encountered very rarely following phenytoin and in isolated cases following carbamazepine and trimethadione administration. Drug-induced systemic lupus erythematosus is much more frequent, with distinct clinical and laboratory abnormalities. The syndrome was described following treatment with most anticonvulsants in clinical use--phenytoin, carbamazepine, ethosuximide, trimethadione, primidone, and valproate, but not phenobarbital or benzodiazepines. The early recognition of these syndromes as being related to drugs is important, because they usually remit upon withdrawal of the offending agent.

Collaboration


Dive into the Vivian E. Drory's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Beatrice Nefussy

Tel Aviv Sourasky Medical Center

View shared research outputs
Top Co-Authors

Avatar

Galina B. Groozman

Tel Aviv Sourasky Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge